Please login to the form below

Not currently logged in
Email:
Password:

Roche’s Tecentriq combo scores in first-line melanoma

Plans to file treatment with health authorities on strength of data

Tecentriq

Roche’s efforts to bolster its checkpoint inhibitor Tecentriq have paid off in melanoma, following a late-stage combination success. 

Tecentriq (atezolizumab), in combination with Genentech’s MEK-inhibitor Cotellic (cobimetinib) and BRAF-inhibitor Zelboraf (vemurafenib) reduced the risk of disease progression or death in BRAF-positive melanoma compared to the placebo plus Cotellic/Zelboraf arm.

Although Roche has not revealed the detailed data from the phase 3 study – named IMspire150 – it has said that the therapy combination demonstrated a clinically meaningful improvement in progression-free survival.

The safety and tolerability profile was also consistent with the known safety profiles of all three medicines.

“By combining a cancer immunotherapy with targeted therapies, we hope to offer a new approach that improves outcomes for people with advanced, BRAF-mutant melanoma." said Levi Garraway, chief medical officer and head of global product development.

"We look forward to discussing the results with health authorities around the world,” he added.

The positive results will be a welcome burst of hope for Roche after Tecentriq failed to hit the mark in an earlier study testing Tecentriq in combination with Cotellic as a third-line treatment option for colorectal cancer.

Those results had cast a shadow on Roche’s extensive plans for the Tecentriq/Cotellic combination, especially the Imspire150 study. However, it seems that the addition of a BRAF-inhibitor has countered those earlier results, and a pay off in the first-line setting could generate impressive sales for Roche.

For Roche, it looks like combination treatments are paving the way for success, after its Tecentriq/chemotherapy combo scored approval from the FDA earlier this month as a first-line treatment for non-small cell lung cancer (NSCLC).

The myriad of combinations in development could help Roche to take more market share from Merck & Co’s class-leader Keytruda (pembrolizumab), which has transformed the standard of care for a number of cancers, particularly NSCLC.

Roche also has plans to file a Tecentriq/Avastin combination treatment for liver cancer. A recent positive trial readout supports these plans as Roche looks to boost Tecentriq, which was a latecomer to the checkpoint inhibitor market.

The full, detailed results are set to be presented at an upcoming medical meeting, and Roche is also planning to take them to global drug regulators, including the FDA and EMA.

Article by
Lucy Parsons

16th December 2019

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics